The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) shows a weighted average implied analyst target price of $47.70, representing a potential 18.92% upside from its recent price of $40.11. Within the ESML holdings, Vaxcyte Inc (PCVX), Nurix Therapeutics Inc (NRIX), and MannKind Corp (MNKD) exhibit the most significant upside potential based on analyst target prices, with potential gains of 263.14%, 148.54%, and 128.44% respectively; however, investors should conduct further research to determine the validity of these targets.
The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) presents a weighted average implied analyst target price of $47.70 per unit, suggesting an 18.92% upside from its recent trading price of $40.11. This potential is significantly driven by specific underlying holdings, most notably Vaxcyte Inc (PCVX), Nurix Therapeutics Inc (NRIX), and MannKind Corp (MNKD). PCVX exhibits an extraordinary average analyst target of $122.89, implying a 263.14% increase from its $33.84 recent price. Similarly, NRIX and MNKD show substantial analyst-projected upsides of 148.54% (target $30.22 vs. recent $12.16) and 128.44% (target $9.94 vs. recent $4.35), respectively, with per-ticker sentiment scores indicating high optimism for these individual biotech firms (0.9 for PCVX, 0.8 for NRIX and MNKD). While the ETF itself carries a more moderate positive sentiment (0.5), the overall article tone is speculative, and it explicitly questions the justification for such high targets, urging further investor research. The low market impact score (0.3) suggests the analysis itself is more observational than market-moving, highlighting potential opportunities contingent on target validation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.15
Ticker Sentiment
